AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 262 min read$PAHC

Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars

Phibro Animal Health (PAHC) reported Q2 CY2026 revenue of $396.7M, up 4.8% YoY, exceeding estimates. Full-year guidance was raised 1.9% above consensus. Non-GAAP EPS of $0.85 beat estimates by 17.1%. The stock rose 7.3% post-earnings.

Original reporting
financialcontent.com
Published Aug 26, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars — source image
Source · financialcontent.com
Decision brief

The 30-second read

$PAHCBullishHigh
01

Why it matters

Earnings beat and raised guidance drove a 7.3% price jump, indicating strong market reaction.

02

Market read

First‑report earnings beat with guidance lift; actionable for short‑term traders.

03

What to watch

Rising input costs and potential regulatory scrutiny on veterinary antibiotics.

Relevance 8/10Novelty 8/10Timing: post‑market earnings release

Background

Phibro Animal Health provides health products for livestock and companion animals across 90 countries.

Company-level read

Ticker impact

$PAHCBullishHigh confidence
Context

Q2 2026 earnings beat revenue and EPS estimates, raised full-year guidance, and stock jumped 7.3% after release.

Expected impact

Potential further rally if guidance holds; watch for pull‑back on profit‑taking.

Evidence & confidence

Revenue up 4.8% YoY, EPS $0.85 vs $0.57 a year ago, guidance 1.9% above consensus; market already reacted positively.

Market effects

Sector

Strong animal‑health demand may lift peer livestock‑product makers.

Regional

Positive for U.S. agribusiness exposure.

Global

Highlights resilience in livestock supply chains worldwide.

Counterpoint

What could challenge this read

Guidance deceleration could signal upcoming slowdown; caution on over‑extension.

Key entities

  • Company
    Phibro Animal Health

    Animal health products manufacturer reporting Q2 2026 results.

Read at source← All news

Related articles

SEP 5
$PAHCMedAI 8/10

Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain?

Phibro Animal Health (PAHC) issued 2027 guidance, projecting net sales of $1.55b-$1.60b and net income of $122m-$132m. The company reported 2026 sales of $1.518b and net income of $99.72m. Analysts' price targets range from $38 to $58, with a consensus of $45.60, suggesting a 16.1% undervaluation. The stock has seen a 90-day return of 17.95% and a 3-year return above 200%.

yahoo.com3 min
SEP 1
$PAHCHighAI 8/10

Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year

Phibro Animal Health (PAHC) reported fiscal 2026 net sales of $1.5B, adjusted EBITDA up 39% to $255M, and EPS up 48% to $3.22. The growth was driven by a recent acquisition and organic growth across segments. Guidance for fiscal 2027 expects slower growth with net sales of $1.55B-$1.6B and EBITDA of $258M-$268M. Free cash flow was $9.9M due to inventory buildup, with debt at $737.9M and a leverage ratio of 2.9x EBITDA.

yahoo.com3 min
AUG 31
$PAHCHighAI 8/10

Phibro (PAHC) Q4 2026 Earnings Call Transcript

Phibro (PAHC) reported Q4 2026 net sales of $396.7M, up 5%, and adjusted EBITDA of $255M, up 39% YoY. Full-year sales reached $1.518B, up 17%, with adjusted EBITDA up 39%. CEO Dani Bendheim highlighted strong performance across segments, including a 20% increase in Mineral Nutrition sales. The company provided fiscal 2027 guidance, expecting net sales of $1.55B-$1.6B and adjusted EBITDA of $258M-$268M. Phibro also announced the closure of a Chicago facility and discussed regulatory uncertainties

yahoo.com2 min
AUG 27
$PAHCHighAI 8/10

Phibro Animal Health Q4 Earnings Call Highlights

Phibro Animal Health (PAHC) reported Q4 and full-year 2026 results, with legacy MFA and other revenue up 4%, Nutritional Specialties up 9%, and vaccine revenue up 14%. The company expects fiscal 2027 sales of $1.55B-$1.60B and adjusted EBITDA of $258M-$268M, with growth driven by acquired MFA products and international demand. However, Brazil regulatory uncertainty and higher input costs may impact performance. Phibro also plans to close its Chicago Heights facility, expecting $15M-$20M in annua

yahoo.com2 min
AUG 26
$PAHCHigh

PHIBRO ANIMAL HEALTH CORP (PAHC): Results of Operations and Financial Condition

PHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ For Immediate Release ​ Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance ​ TEANECK, N.J., August 26, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) tod

SEC EDGAR 8-K2 min